Search the Newsreel

Beta Technologies, Inc. (BETA) faces earnings after 52.6% 12-week advance

The electric-aircraft maker has stronger recent trading behind it, but inactive trend confirmation keeps the setup mixed.

BETA (BETA) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Head of Investor Relations - Devon RothmanFounder and Chief Executive Officer - Kyle ClarkChief Financial Officer - Herman CuetoHead of Government and Regulatory Affairs - Kristen Costello TAKEAWAYS …

BETA Technologies Inc (BETA) (Q2 2026) Earnings Call Highlights: Revenue Surges 146% as ...

This article first appeared on GuruFocus. Release Date: August 12, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Revenue in Q2 2026 was $14.7 million, exceeding guidance and up 146% year-over-year, driven by …

BETA Technologies (NYSE: BETA) grows revenue but widens loss on heavy R&D

BETA Technologies (NYSE: BETA) reported a significant increase in revenue for the first half of 2026, reaching $24.791 million, a 59% year-over-year growth, primarily from engineering and consulting services. Despite this revenue growth, the company's net loss widened to $271.062 million, up 71% from …

BETA Technologies Posts 146% Revenue Jump in Q2 2026, Misses on EPS

BETA Technologies Q2 Earnings Call Highlights

BofA Securities Maintains Beta Bionics(BBNX.US) With Hold Rating, Raises Target Price to $18

BofA Securities has maintained its Hold rating on Beta Bionics (BBNX.US) and increased its target price for the company's stock to $18. This adjustment reflects BofA's updated outlook for Beta Bionics.

Earnings call transcript: BETA Technologies misses Q2 2026 EPS as shares fall

This article first appeared on GuruFocus. Release Date: August 12, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Revenue in Q2 2026 was $14.7 million, exceeding guidance and up 146% year-over-year, driven by …

BETA Technologies Announces Q2 2026 Financial Results and Hosts Conference Call

BETA Technologies, Inc. filed its Q2 2026 financial results with the SEC on August 12, 2026, through a Form 8-K. The report details the company's financial and operational performance for the quarter ending June 30, 2026. A conference call was held on the same …

BETA Technologies, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:BETA) 2026-08-12

Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Head of Investor Relations - Devon RothmanFounder and Chief Executive Officer - Kyle ClarkChief Financial Officer - Herman CuetoHead of Government and Regulatory Affairs - Kristen Costello TAKEAWAYS …

Beta Technologies shares fall on deeper-than-expected loss (BETA:NYSE)

BETA Technologies, Inc. Raises Earnings Guidance for the Full Year 2026

BETA Technologies stock falls 4% on wider-than-expected loss

Earnings Flash (BETA) BETA Technologies, Inc. Reports Q2 Revenue $14.7M

BETA Technologies (BETA) Earnings Date and Reports 2026

Beta Technologies CEO Clark Kyle disposes of common shares worth $1.17 million

Beta Technologies CEO, President, and director Kyle Clark sold 47,896 Class A common shares between August 7-11, 2026, for a total value of approximately $1.17 million. The sales were executed at weighted-average prices ranging from $23.25 to $24.46 per share. Following these transactions, the …

BETA Technologies (BETA) CEO-affiliated trust sells 47,896 shares in planned trades

The Godric's Hollow Trust, an entity affiliated with BETA Technologies President and CEO Clark Kyle, sold a total of 47,896 shares of Class A common stock in open-market transactions on August 7, 10, and 11, 2026. These sales were conducted under a pre-established Rule …

Beta Bionics, Inc. Stock 12‑Month Price Target Raised to $20.31, Implies 24% Upside

Beta Bionics, Inc. (BBNX) has seen its average 12-month price target raised from $20.08 to $20.31 by 11 analysts, with forecasts ranging from $14 to $30.4 per share. This new target implies a potential upside of approximately 24% from its August 10 closing price. …

BETA ENERJİ VE TEKNOLOJİ A.Ş.(BETAE) Katılım Finansı İlkeleri Bilgi Formu 10 Ağustos 2026

Beta Bionics (NASDAQ:BBNX) Shares Up 13.7% - Should You Buy?

Beta Bionics (NASDAQ:BBNX) saw its shares surge by 13.7% to $16.05, trading above its 50-day and 200-day moving averages, though its high beta of 3.13 indicates significant volatility. Analysts hold a "Moderate Buy" consensus with a $20.10 price target, despite one firm issuing a …

Operating expenses (excl. COGS) of BETA Technologies, Inc. Class A – HAM:9N8

This article provides financial data on the operating expenses (excluding COGS) for BETA Technologies, Inc. Class A, traded on the Hamburg Stock Exchange under the ticker 9N8. The information is presented within the TradingView platform, noting that the market is currently closed with no …

Lazard Asset Management LLC Buys New Holdings in Beta Bionics, Inc. $BBNX

Lazard Asset Management LLC has acquired a new stake of 71,905 shares in Beta Bionics (NASDAQ:BBNX), valued at approximately $720,000, representing 0.16% ownership. Other institutional investors also established or increased positions in the company. Beta Bionics shares recently traded down 4.5% at $13.91, with …

BETA Technologies, Inc. Class A Trade Ideas — HAM:9N8

This article compiles several trade ideas and analyses for BETA Technologies, Inc. (HAM:9N8), an electric aerospace company. It includes both bullish and bearish cases for the stock, detailed technical analysis concepts like "Candle Science," and specific long trading strategies from different contributors. The company's …

Beta Bionics (Nasdaq: BBNX) lifts Q2 sales to $32M amid ongoing losses

Beta Bionics (Nasdaq: BBNX) reported a significant increase in Q2 2026 net sales to $32.0 million, up from $23.2 million a year prior, primarily driven by its iLet insulin delivery device and single-use consumables. Despite this growth, the company continues to experience substantial losses, …

Beta Bionics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:BBNX) 2026-07-31

Beta Bionics, Inc. (BBNX) published its Q2 2026 earnings call presentation, reporting an EPS of -$0.36, beating estimates by $0.20, and revenue of $32.01M, surpassing expectations by $533.03K with a 37.76% year-over-year increase. The slide deck was released in conjunction with the company's earnings …

A Quick Look at Today's Ratings for Beta Bionics(BBNX.US), With a Forecast Between $15.5 to $30.4

This article provides an overview of recent analyst ratings for Beta Bionics (BBNX.US), highlighting a forecast range for its stock price between $15.5 and $30.4. It appears to be a summary of current market sentiment regarding the company's valuation.

Beta Bionics Earnings Call Highlights Growth And Risks

Beta Enerji Hangi Bankalarda Var? BETAE Halka Arz Nasıl Alınır, Kaç Lot Verir, Katılım Endeksine Uygun Mu?

Law firm probes Beta Bionics for possible misleading growth claims affecting investors

Johnson Fistel, PLLP is investigating Beta Bionics for potential securities law violations due to allegedly misleading statements about its growth and new patient starts. This probe was triggered by Beta Bionics' disclosure of significantly slower growth in new patient starts for Q4 2025, which …

Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders

Johnson Fistel, PLLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) for potential securities law violations after the company disclosed slower new patient start growth for Q4 2025, which fell below analyst expectations and showed significant deceleration from the previous quarter. The law firm is …

Healthcare of Ontario Pension Plan Trust Fund Lowers Stake in Beta Bionics, Inc. $BBNX

Beta Drugs Standalone June 2026 Net Sales at Rs 55.83 crore, down 15.83% Y-o-Y

Beta Drugs Ltd. Revenue Breakdown – NSE:BETA